Table 4.
Contribution of HO-1 up-regulation to the biological effects of resveratrol in preclinical in vitro and in vivo models.
| Preclinical model | Resveratrol (concentration or dose) | Effect(s) | Reference(s) |
|---|---|---|---|
| Kidney injury in rats | 30 mg/kg i.p. | Amelioration of sepsis-induced kidney injury | (Wang et al., 2018a) |
| Renal cells | 20 µM | Cytoprotection from nicotine-induced oxidative damage. | (Arany et al., 2017) |
| Lung injury in rodents | 30 mg/kg i.p. 1–3 mg/kg per os for 3 days |
Improvement of sepsis- or paraquat-induced lung injury in rats Enhancement of cell stress response and attenuation of cigarette smoke-induced damage in mice |
(Li et al., 2016; Wang et al., 2018b) (Liu et al., 2014) |
| Renal carcinoma in rats | 30 mg/kg per os for 24 weeks | Inhibition of proliferation and improvement of renal function; increase in the antioxidant system | (Kabel et al., 2018) |
| Membranous nephropathy in mice | 30 mg/kg s.c. every other day for 6 weeks | Reduction of apoptosis and complement-induced damage; amelioration of renal function | (Wu et al., 2015) |
| Endothelial cells | 0.01–10 µM | Reduction of oxidative stress-induced damage and inhibition of senescence in progenitor cells | (Shen et al., 2016b) |
| Smooth muscle cells | 1–10 µM | Inhibition of oxidative damage and inflammation; vascular protection | (Juan et al., 2005) |
| Obstructive jaundice in rats | 10–20 mg/kg per os | Restoration of intestinal permeability and improvement of gut barrier function | (Wang et al., 2016a) |
| Gastric inflammation in mice | 100 mg/kg per os for 6 weeks | Reduction of oxidative damage and inflammation in Helicobacter pylori–infected gastric mucosa | (Zhang et al., 2015) |
| Myocardial damage in rats | 100 µM i.v. | Reduction of oxidative damage and improvement of cardiac function following ischemia/reperfusion injury | (Cheng et al., 2015) |
| Hepatoma cells | 1 µM | Stimulation of mitochondrial biogenesis and reduction of inflammatory damage | (Kim et al., 2014) |
| Macrophages | 1–10 µM | Inhibition of inflammatory damage | (Son et al., 2014) |
i.p., intraperitoneal route of administration; i.v., intravenous route of administration; s.c., subcutaneous route of administration.